The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the blood profile of the N-methylnicotinamide
(MNA) following administration of TRIA-662 (N-methylnicotinamide Chloride). The secondary
objectives of the study are to characterize the safety and tolerability of TRIA-662 and to
assess any potential gender-related differences in the plasma profile of MNA. Changes in
serum lipid parameters with particular reference to triglycerides, lipoprotein lipase, and
blood pressure effects will also be noted.